Back to Journals » OncoTargets and Therapy » Volume 9

Association between three exonuclease 1 polymorphisms and cancer risks: a meta-analysis

Authors Chen Z, Zheng S, Zhong JH, Zhuang X, Zhou J

Received 27 August 2015

Accepted for publication 10 December 2015

Published 23 February 2016 Volume 2016:9 Pages 899—910

DOI https://doi.org/10.2147/OTT.S95258

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Professor Da Li

Peer reviewer comments 3

Editor who approved publication: Professor Daniele Santini


Zi-Yu Chen,1,2 Si-Rong Zheng,2 Jie-Hui Zhong,1,2 Xiao-Duan Zhuang,1,2 Jue-Yu Zhou2

1Department of Clinical Medicine, The First Clinical Medical College, Southern Medical University, 2Institute of Genetic Engineering, School of Basic Medical Sciences, Southern Medical University, Guangzhou, People’s Republic of China

Abstract: To date, the results of studies exploring the relation between exonuclease 1 (Exo1) polymorphisms and cancer risks have differed. In this study, we performed a meta-analysis to investigate the effect of the three most extensively studied Exo1 polymorphisms (Pro757Leu, Glu589Lys, and Glu670Gly) on cancer susceptibility. The related studies published before August 5, 2015, were collected by searching the PubMed and EMBASE databases. We found 16 publications containing studies that were eligible for our study, including 10 studies for Pro757Leu polymorphism (4,093 cases and 3,834 controls), 12 studies for Glu589Lys polymorphism (6,479 cases and 6,550 controls), and 7 studies for Glu670Gly polymorphism (3,700 cases and 3,496 controls). Pooled odds ratios and 95% confidence intervals were used to assess the strength of the associations, and all the statistical analyses were calculated using the software program STATA version 12.0. Our results revealed that the Pro757Leu polymorphism was significantly associated with a reduced cancer risk, whereas an inverse association was found for the Glu589Lys polymorphism. Furthermore, subgroup analysis of smoking status indicated that the Glu589Lys polymorphism was significantly associated with an increased cancer risk in smokers, but not in nonsmokers. However, no evidence was found for an association between the Glu670Gly polymorphism and cancer risk. In conclusion, this meta-analysis suggests that the Pro757Leu polymorphism may provide protective effects against cancer, while the Glu589Lys polymorphism may be a risk factor for cancer. Moreover, the Glu670Gly polymorphism may have no influence on cancer susceptibility. In the future, large-scaled and well-designed studies are needed to achieve a more precise and comprehensive result.

Keywords: exonuclease 1, polymorphism, cancer risks, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]